SDS Biotech K.K. reported consolidated earnings results for the six months ended September 30, 2016. For the quarter, the company reported net sales of ¥5,618 million against ¥7,242 million a year ago. Operating income was ¥183 million against ¥402 million a year ago. Ordinary income was ¥363 million against ¥231 million a year ago. Net income attributable to owners of parent was ¥127 million or ¥16.25 per basic share against ¥181 million or ¥23.13 per basic and diluted share a year ago. Net loss before income taxes and non-controlling interest was ¥362,860,000 compared to income of ¥232,027,000 a year ago. Net cash used in operating activities of ¥202,114,000 compared to ¥1,721,719,000 a year ago. Purchase of property, plant and equipment was ¥93,345,000 compared to ¥108,220,000 a year ago. Purchase of intangible assets was ¥17,013,000 compared to ¥30,369,000 a year ago.

For the fiscal year ending March 31, 2017, the consolidated company expects net sales of ¥16,210 million, operating income of ¥1,460 million, ordinary income of ¥1,220 million and net income of ¥820 million or ¥104.71 per share.